KSB, Sosei TransMID deal

KS Biomedix (LSE:KSB) granted Sosei (Tokyo, Japan) Japanese rights to its Phase II TransMID treatment for recurrent high grade glioma. KSB will manufacture and sell TransMID materials for Sosei, which...